Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Correction to: CART cells are prone to Fas- and DR5-mediated cell death.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A.

J Immunother Cancer. 2018 Sep 25;6(1):92. doi: 10.1186/s40425-018-0410-2.

2.

Mechanisms regulating T-cell infiltration and activity in solid tumors.

Lanitis E, Dangaj D, Irving M, Coukos G.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32. doi: 10.1093/annonc/mdx238.

PMID:
29045511
3.

Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

Facciabene A, De Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, Rueter J, Kagabu M, Magotti P, Lanitis E, DeAngelis RA, Buckanovich RJ, Song WC, Lambris JD, Coukos G.

Oncoimmunology. 2017 Jun 8;6(9):e1326442. doi: 10.1080/2162402X.2017.1326442. eCollection 2017.

4.

Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.

Roberti A, Dobay MP, Bisig B, Vallois D, Bo├ęchat C, Lanitis E, Bouchindhomme B, Parrens MC, Bossard C, Quintanilla-Martinez L, Missiaglia E, Gaulard P, de Leval L.

Nat Commun. 2016 Sep 7;7:12602. doi: 10.1038/ncomms12602.

5.

Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Smith JB, Lanitis E, Dangaj D, Buza E, Poussin M, Stashwick C, Scholler N, Powell DJ Jr.

Mol Ther. 2016 Nov;24(11):1987-1999. doi: 10.1038/mt.2016.149. Epub 2016 Jul 21.

6.

Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.

Karapetsas A, Giannakakis A, Dangaj D, Lanitis E, Kynigopoulos S, Lambropoulou M, Tanyi JL, Galanis A, Kakolyris S, Trypsianis G, Coukos G, Sandaltzopoulos R.

Biomed Res Int. 2015;2015:712438. doi: 10.1155/2015/712438. Epub 2015 Sep 13.

7.

Targeting the tumor vasculature to enhance T cell activity.

Lanitis E, Irving M, Coukos G.

Curr Opin Immunol. 2015 Apr;33:55-63. doi: 10.1016/j.coi.2015.01.011. Epub 2015 Feb 6. Review.

8.

A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes.

Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, Czerniecki BJ, Li YF, Robbins PF, Powell DJ Jr.

Hum Gene Ther. 2014 Aug;25(8):730-9. doi: 10.1089/hum.2014.006.

9.

Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.

Giannakakis A, Karapetsas A, Dangaj D, Lanitis E, Tanyi J, Coukos G, Sandaltzopoulos R.

Int J Biochem Cell Biol. 2014 Aug;53:389-98. doi: 10.1016/j.biocel.2014.05.031. Epub 2014 May 29.

PMID:
24880093
10.

Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.

Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ Jr.

Cancer Immunol Res. 2013 Jul;1(1):43-53.

11.

Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.

Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, Powell DJ Jr, Scholler N.

Cancer Res. 2013 Aug 1;73(15):4820-9. doi: 10.1158/0008-5472.CAN-12-3457. Epub 2013 May 30.

12.

Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.

Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, Coukos G, Powell DJ Jr.

PLoS One. 2012;7(11):e49829. doi: 10.1371/journal.pone.0049829. Epub 2012 Nov 26.

13.

A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.

Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ Jr.

Cancer Res. 2012 Apr 1;72(7):1844-52. doi: 10.1158/0008-5472.CAN-11-3890. Epub 2012 Feb 7.

14.

Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.

Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr.

Mol Ther. 2012 Mar;20(3):633-43. doi: 10.1038/mt.2011.256. Epub 2011 Nov 29.

15.

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.

Chiang CL, Maier DA, Kandalaft LE, Brennan AL, Lanitis E, Ye Q, Levine BL, Czerniecki BJ, Powell DJ Jr, Coukos G.

J Transl Med. 2011 Nov 14;9:198. doi: 10.1186/1479-5876-9-198.

16.

Reactive oxygen species and HIF-1 signalling in cancer.

Galanis A, Pappa A, Giannakakis A, Lanitis E, Dangaj D, Sandaltzopoulos R.

Cancer Lett. 2008 Jul 18;266(1):12-20. doi: 10.1016/j.canlet.2008.02.028. Epub 2008 Apr 18. Review.

PMID:
18378391

Supplemental Content

Loading ...
Support Center